Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1205c with Osimertinib in EGFR-Mutant NSCLC
NCT03255083Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-1205 in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting Toxicities and Treatment-emergent Adverse Events up to 1 year. Started Apr 2019; status: terminated.
02
Drugs
DS-1205
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03255083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255083.